Pathos AI, Inc.
Category: AI in Healthcare
An AI-enabled biotechnology company re-engineering drug development using machine learning and real-world clinical and molecular data to advance precision oncology therapeutics. Pathos AI, Inc. was founded in 2022. The company is led by Iker Huerga. Based in Chicago, IL, USA. Team size: 51-200. Total funding raised: ~$467M total (all rounds). Latest round: Series D ($365M, May 2025 at ~$1.6B valuation - unicorn status). Key investors include New Enterprise Associates (NEA), Revolution Growth, General Catalyst, Deerfield Management, ARCH Venture Partners, Tempus Labs.
- Founded
- 2022
- Headquarters
- Chicago, IL, USA
- Team size
- 51-200
- Total funding
- ~$467M total (all rounds)
Value proposition
Leveraging proprietary AI and extensive clinical data to accurately identify patient subpopulations, acquire or license targeted clinical-stage therapies, and de-risk the drug development process in precision oncology.
Products and solutions
Foundry / PathOS™ Platform: Proprietary AI platform (Pathos Oncology Foundation Model + thousands of AI agents) for asset ID, patient stratification, portfolio decisions, and trial design. Pocenbrodib (P-300/FT-7051): CBP/p300 inhibitor, Phase 1b/2a in mCRPC (licensed from Novo Nordisk). P-500 (PRT811): Brain-penetrant PRMT5 inhibitor for solid tumors (licensed from Prelude Therapeutics 2024). DO-2: Third-generation MET kinase inhibitor via majority stake in DeuterOncology (May 2026).
Unique value
Integrates large-scale real-world patient data with a proprietary AI platform to identify unique biological mechanisms and patient subtypes, subsequently acquiring or licensing clinical-stage assets for focused development.
Target customer
Biopharmaceutical companies (for strategic partnerships and co-development) and cancer patients as ultimate beneficiaries
Industries served
Biotechnology, Pharmaceuticals, Healthcare, Oncology
Technology advantage
Access to large-scale multimodal oncology datasets; Foundry / PathOS™ platform (Pathos Oncology Foundation Model with thousands of AI agents for asset ID, portfolio decisions, and trial execution); strategic data partnership with Tempus AI and multi-party foundation model work with AstraZeneca; leadership links to Tempus Labs.
How they differentiate
Focuses on the identification and acquisition/licensing of existing clinical-stage assets through precise AI-driven patient stratification rather than pursuing a solely de novo drug discovery approach.
Main competitors
Tempus Labs, Recursion Pharmaceuticals, Exscientia, BenevolentAI, Insitro
Key partnerships
Tempus AI (strategic data partnership, multi-year oncology foundation model collaboration with AstraZeneca, Apr 2025), AstraZeneca (multi-year multimodal oncology foundation model with Tempus and Pathos), Novo Nordisk (pocenbrodib/P-300/FT-7051 license), Prelude Therapeutics (P-500/PRT811 license, 2024), DeuterOncology (majority stake acquisition May 2026 for DO-2), Rain Oncology (acquired Dec 2023)
Notable customers
Biopharmaceutical partners: Novo Nordisk (pocenbrodib license), Prelude Therapeutics (P-500 license), AstraZeneca and Tempus AI (oncology foundation model collaboration), acquired/partnered assets from Rain Oncology and DeuterOncology
Major milestones
Spun out from Tempus Labs in 2022, Closed Series A (~$15M, Nov 2022), Closed Series B (~$25–32M, Mar 2023), Licensed pocenbrodib (P-300/FT-7051) from Novo Nordisk (May 2023), Acquired Rain Oncology (Dec 2023), Licensed P-500 (PRT811) from Prelude Therapeutics (2024), Closed Series C ($62M, Oct 2024, total funding $102M, $600M valuation)
Growth metrics
Not publicly disclosed; however, successive funding rounds and asset acquisitions indicate robust growth.
Market positioning
A clinical-stage, precision oncology company that distinguishes itself with a hybrid model of data-driven asset acquisition.
Geographic focus
Primarily United States
Patents and IP
Pending patent filings covering proprietary algorithms and platform components.
About Iker Huerga
Iker Huerga has over 20 years of experience in applying Data Science and Artificial Intelligence to oncology drug development. He was previously the Chief Data Scientist for Oncology R&D at AstraZeneca and an Executive Vice President at Tempus Labs. He is also a serial biotech entrepreneur, having founded three oncology companies with two successful exits.
Latest news about Pathos AI, Inc.
More AI in Healthcare companies
Official website: https://pathos.com/